Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Hutson on Remaining Questions With the Durability of Immune Responses in RCC

November 12th 2020

Thomas Hutson, DO, PharmD, discusses remaining questions regarding the durability of responses to immunotherapy in patients with renal cell carcinoma.

Dr. Zhang on the Combination of LAG525 and Spartalizumab in Advanced Malignancies

November 12th 2020

Tian Zhang, MD, discusses the combination of ieramilimab and spartalizumab in advanced malignancies.

Antibody-Drug Conjugates Carve Out Space in Urothelial Carcinoma Landscape

November 12th 2020

Monoclonal antibodies have played a key role in the development of personalized oncology and have proven antitumor activity through multiple mechanisms, including direct transmembrane signaling leading to apoptosis, complement mediated cytotoxicity, antibody-dependent cellular cytotoxicity, and inhibiting tumor vasculature and stroma.

First Nonoperative Option Arrives for Low-Grade UTUC

November 11th 2020

Seth P. Lerner, MD, FACS, discusses the complexities of treating LG-UTUC and how mitomycin gel for instillation addresses an unmet need in this space.

Frontline Pembrolizumab/Lenvatinib Significantly Improves Survival, Responses in Advanced RCC

November 10th 2020

November 10, 2020 - The combination of pembrolizumab plus lenvatinib significantly improved progression-free survival, overall survival, and the objective response rate compared with sunitinib, when used in the frontline treatment of patients with advanced renal cell carcinoma.

Surgical Delays Caused By COVID-19 Do Not Increase Risk of pT3a Upstaging, Compromise OS in cT1b-cT2b RCC

November 9th 2020

The coronavirus disease 2019 pandemic has led to delays in elective and potentially curative surgeries for patients with cT1b-cT2b renal cell carcinoma but research has indicated that surgical delays of up to and beyond 3 months did not result in an increased risk of pT3a upstaging or comprise overall survival.

Clinical Activity, Safety of Modified Nivolumab/Ipilimumab Dose in RCC Confirm Best Practices

November 7th 2020

A modified dosing schedule of frontline nivolumab (Opdivo) and ipilimumab (Yervoy) compared with the standard dose showed no differences in responses or safety in patients with advanced renal cell carcinoma, according to results of the CheckMate-920 trial.

Low-Dose Lenvatinib Shows Similar Safety to Standard Dose in RCC, But Noninferiority Cannot Be Claimed

November 7th 2020

A 14-mg dose of lenvatinib showed similar safety to the standard 18-mg dose of the agent, when used in combination with everolimus in the second-line treatment of patients with advanced renal cell carcinoma, but noninferiority could not be confirmed.

Future of VHL Disease–Associated RCC Bright, With Immunotherapy and HIF-2α, CDK4/6 Inhibitors Part of Ongoing Research

November 7th 2020

Recent research for effective therapies designed to target von Hippel-Lindau disease–associated renal cell carcinoma is pointing to a future with the paradigm that comprises immunotherapy, HIF-2α inhibitors, and potentially CDK4/6 inhibitors.

Choosing Among First-Line IO/TKI Combos in RCC: The Affordable Option Is the Winner

November 7th 2020

Combination regimens comprised of immunotherapy and TKI inhibitors have yielded significant benefits in terms of overall survival and progression-free survival with acceptable safety in patients with renal cell carcinoma; however, the cost of these regimens may negate the impact of these advances.

Dr. McGregor the Potential Utility of Cabozantinib/Nivolumab in Advanced RCC

November 7th 2020

Bradley McGregor, MD, discusses the potential utility of the combination of cabozantinib and nivolumab in advanced renal cell carcinoma (RCC).

Dr. Choueiri on the Rationale for the COSMIC-313 Trial in Advanced RCC

November 7th 2020

Toni K. Choueiri, MD, discusses the rationale for the phase 3 COSMIC-313 trial in advanced renal cell carcinoma.

Lenvatinib/Pembrolizumab Shows Promise After PD-1/PD-L1 Inhibition in Metastatic Clear Cell RCC

November 6th 2020

The combination of lenvatinib plus pembrolizumab demonstrated encouraging antitumor activity in patients with metastatic clear cell renal cell carcinoma who had progressed on prior PD-1 or PD-L1 immune checkpoint inhibitor therapy.

Dr. Rini on Choosing Between IO/IO or IO/TKI Combinations in mRCC

November 6th 2020

Brian I. Rini, MD, discusses choosing between combinations of dual immunotherapy and immunotherapy/VEGF TKIs in metastatic renal cell carcinoma.

Frontline Lenvatinib/Everolimus Combo Is Active in Non-Clear Cell RCC

November 6th 2020

The first-line combination of lenvatinib and everolimus elicited clinical activity in patients with advanced non-clear cell renal cell carcinoma.

Cabozantinib Is Center of Emerging Treatment Approaches in Advanced RCC

November 6th 2020

Toni K. Choueiri, MD, discusses key findings from the CheckMate-9ER trial in advanced RCC, as well as ongoing trials with the potential to shift the paradigm even further.

Dr. Srinivasan on the Challenges of Developing New Therapies in Rare RCC Subtypes

November 4th 2020

Ramaprasad Srinivasan, MD, PhD, discusses the challenges of developing new therapies to treat patients with rare renal cell carcinoma subtypes.

KidneyCAN 2020 Touts Power of Translational Research in Advancing RCC Field

November 3rd 2020

The 2020 Kidney Cancer Research Summit (KidneyCAN) featured several healthcare experts who highlighted the latest clinical developments, critical preclinical efforts, and translational research being performed to move the needle forward in the field of kidney cancer.

ESMO 2020 Highlights With Cora Sternberg, MD, FACP

October 30th 2020

TROPHY U-01 cohort 1 is a phase 2 open-label study of sacituzumab govitecan in patients with metastatic urothelial cancer and disease progression after both platinum-based regimens and checkpoint inhibitors.

Dr. Henske on the Potential Role of Glutathione in Chromophobe RCC

October 28th 2020

Elizabeth Petri Henske, MD, discusses the potential role of glutathione in chromophobe renal cell carcinoma.